Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis is a research paper published in Cancers (2021). On theSindex it has a DataRank of 0. It has been cited 18 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH HHS
Grant: 1F32CA247067-01A1
Tumor-derived Exosome Induction of Dendritic Cell Tolerization
Office of Extramural Research, National Institutes of Health
Grant: 1R37CA249085-01S1
Duke University
Grant: Duke Scholar Award
Damon Runyon Cancer Research Foundation
Grant: Physician Scientist Award
Duke University
Grant: Strong Start Award
Conquer Cancer Foundation
Grant: Advanced Clinical Research Award in Immune Checkpoint Inhibitor Therapy
NCI NIH HHS
Grant: R37 CA249085
Office of Extramural Research, National Institutes of Health
Grant: 1R37CA249085-01
Merck
Grant: Pre-Clinical Research Grant
National Institutes of Health
Grant: 5R37CA249085-04
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
FWCI
0.89
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals